David R. Maraldo - 05 Aug 2026 Form 4 Insider Report for Merck & Co., Inc. (MRK)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
07 Aug 2026, 16:21:19 UTC
Prior SEC filing
07 May 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Kelly E. W. Grez as Attorney-in-Fact for David R. Maraldo

Key filing fact

David R. Maraldo filed Form 4 for Merck & Co., Inc. (MRK) on 07 Aug 2026.

Key facts

  • This page summarizes David R. Maraldo's Form 4 filing for Merck & Co., Inc. (MRK).
  • 9 reported transactions and 3 derivative rows are listed below.
  • Accepted by SEC: 07 Aug 2026, 16:21.

Change

  • Previous filing in this sequence was filed on 07 May 2026.
  • Current net transaction value: -$2,407,797.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002126478 Primary reporting owner

Maraldo David R.

Relationship
EVP & Pres. MMD
Address
126 EAST LINCOLN AVENUE, RAHWAY
Signature
/s/ Kelly E. W. Grez as Attorney-in-Fact for David R. Maraldo
Signature date
07 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MRK transaction

Common Stock

Options Exercise

Transaction value
Shares
+6,311
Change %
+35%
Price
$73.73*
Shares after
24,523
Date
05 Aug 2026
Ownership
Direct
MRK transaction

Common Stock

Sale

Transaction value
$812,339
Shares
-6,311
Change %
-26%
Price
$128.72
Shares after
18,212
Date
05 Aug 2026
Ownership
Direct
Footnotes
F1
MRK transaction

Common Stock

Options Exercise

Transaction value
Shares
+9,709
Change %
+53%
Price
$87.10*
Shares after
27,921
Date
05 Aug 2026
Ownership
Direct
MRK transaction

Common Stock

Sale

Transaction value
$1,249,722
Shares
-9,709
Change %
-35%
Price
$128.72
Shares after
18,212
Date
05 Aug 2026
Ownership
Direct
Footnotes
F1
MRK transaction

Common Stock

Options Exercise

Transaction value
Shares
+2,686
Change %
+15%
Price
$84.71*
Shares after
20,898
Date
05 Aug 2026
Ownership
Direct
MRK transaction

Common Stock

Sale

Transaction value
$345,736
Shares
-2,686
Change %
-13%
Price
$128.72
Shares after
18,212
Date
05 Aug 2026
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MRK transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares
-6,311
Change %
-67%
Price
$0.000000*
Shares after
3,154
Date
05 Aug 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
6,311
Exercise price
$73.73
Footnotes
F2
MRK transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares
-9,709
Change %
-100%
Price
$0.000000*
Shares after
0
Date
05 Aug 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
9,709
Exercise price
$87.10
Footnotes
F3
MRK transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares
-2,686
Change %
-33%
Price
$0.000000*
Shares after
5,374
Date
05 Aug 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
2,686
Exercise price
$84.71
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.6400 to $128.8500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in the footnote.

Footnote F2

The option vested and became exercisable in three equal installments on 5/4/2022, 5/4/2023, and 5/4/2024.

Footnote F3

The option vested and become exercisable in three equal installments on 5/3/2023, 5/3/2024, and 5/3/2025.

Footnote F4

The options vest and become exercisable in three equal installments on 4/29/2026, 4/29/2027, and 4/29/2028.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .